News

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...
Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.
Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...
The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...
Influencers on TikTok have been banned after they were found to be promoting drugs like Ozempic and Mounjaro through their social media ...
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...
Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...
Estonian residents spent more on weight-loss drugs like Ozempic than any other medication last year, with one in every 50 ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.